
Medicare will soon cover a new class of Alzheimer’s drugs if they receive full approval from the U.S. Food and Drug Administration, with some key limits. Along with being full approved, drug makers will also have to gather and keep data in a registry showing how the drugs are working in the real world, the… read on > read on >